Updating data about a first-line modified schedule of gemcitabine with a lower dose than standard in very elderly or PS 2 patients with advanced non-small cell lung cancer

Autor:	Domenico Galetta, M. D' Amico, Palma Fedele, Paola Schiavone, L. Orlando, Saverio Cinieri, Angelo Nacci, A. Marino, Francesco Sponziello, N. Calvani, P. Rizzo, C. Chetri, E. Mazzoni, M. Criscuolo, Margherita Cinefra
Rok vydání:	2011
Předmět:	Oncology Cancer Research Schedule medicine.medical_specialty endocrine system diseases business.industry First line medicine.disease Gemcitabine respiratory tract diseases Internal medicine medicine Poor performance status Non small cell business Lung cancer medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:e18031-e18031
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.e18031
Popis:	e18031 Background: Monochemotherapy with gemcitabine (Gem) is often the treatment of choice in elderly or poor performance status (PS) patients with advanced non-small cell lung cancer (NSCLC). Our...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b5f8ad05de39fab4e92b5b01c8da6d98 https://doi.org/10.1200/jco.2011.29.15_suppl.e18031 Zobrazit plný text záznamu